NCT01916980View on ClinicalTrials.gov

Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Eczema/Dermatitis and Dermal Pruritus (MK-4117-202)

PHASE3CompletedINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

August 27, 2013

Primary Completion Date

March 8, 2014

Study Completion Date

March 22, 2014

Conditions
EczemaDermatitisDermal Pruritus
Interventions
DRUG

Desloratadine 5 mg

Desloratadine 5 mg/day: one 5-mg tablet taken orally once daily in the evening for up to 12 weeks (Desloratadine 10 mg/day: two 5-mg tablets taken orally once daily in the evening for up to 8 weeks)

All Listed Sponsors
lead

Organon and Co

INDUSTRY

NCT01916980 - Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Eczema/Dermatitis and Dermal Pruritus (MK-4117-202) | Biotech Hunter | Biotech Hunter